Cytomegalovirus infection in a patient treated with efalizumab for psoriasis.
Miquel
F Javier
FJ
Colomina
Javier
J
Maríi
Juan I
JI
Ortega
Carmen
C
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018845:CD11 Antigens; D003586:Cytomegalovirus Infections / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections; D011565:Psoriasis / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018845:CD11 Antigens; D007166:Immunosuppressive Agents; C472181:efalizumab